Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

Inclusion Criteria: * HIV-infected * On stable Food and Drug Administration (FDA)-approved antiretrovirals for at least 8 weeks * Excess abdominal fat based on waist and hip measurements done at the screening visit. \[waist greater than 34.7 inches (men) or 29.6 inches (women) and waist to hip ratio greater than 0.95 (men) or 0.9 (women)\] * Evidence of insulin resistance (based on fasting glucose and insulin levels done at screening) * Triglycerides less than 750 mg/dL Exclusion Criteria: * Pregnancy * Active AIDS-defining infection or other acute illness, within 30 days of entry. * Active cancer (except for localized Kaposi's sarcoma) or active brain tumor * Any diagnosis of pancreatitis, carpal tunnel syndrome, diabetes, angina, coronary artery disease, or disorder associated with fluid retention (examples: cirrhosis, congestive heart failure) * Untreated or uncontrolled high blood pressure, within 30 days of entry. * Within 12 weeks of study entry, use of the following: * Obesity (fat-reducing) drugs. * Anti-diabetic or insulin-sensitizing drugs (examples: rosiglitazone, pioglitazone, or metformin). * Systemic glucocorticoids (example: prednisone). * Growth hormone or any medication for AIDS-associated wasting. * Systemic chemotherapy, interferon, or radiation therapy. * Androgenic agents \[examples: nandrolone, oxandrolone (Oxandrin) (testosterone replacement therapy is permitted if started more than 30 days before entry)\] * Appetite stimulants (Marino…